|
|
|
市場調查報告書
中國診斷劑產業報告:2011年∼2012年
China Diagnostic Reagent Industry Report, 2011-2012
|
中國診斷劑產業報告:2011年∼2012年 是由出版商ResearchInChina在2011年10月所出版的。
這份英文市場調查報告書包含60 Pages 價格從美金1500起跳。
本報告提供中國診斷劑產業企業環境分析，以診斷劑產業的發展為焦點，提供主要製造商簡介，為您概述為以下內容。
第1章 產業簡介
第2章 中國企業環境
第3章 中國發展
- 現狀
- 市場規模
- 競爭格局
- 進出口
- 市場區隔
- 診斷劑部門的發展趨勢
第4章 中國主要診斷劑製造商
- Shanghai Kehua Bio-Engineering Co., Ltd. (KHB)
- Da An Gene Co., Ltd. of Sun Yat-SenUniversity
- Fosun Pharmaceutical (Group) Co., Ltd.
- Shanghai Fosun Long March Medical Science Co., Ltd.
- Shanghai Fosun Med-Tech Development Co., Ltd.
- Biosino Bio-Technology & Science Inc.
- Beijing Kinghawk Pharmaceutical Co., Ltd.
- Zhuhai Livzon Diagnostics Inc.
- ACON Biotech (Hangzhou) Co., Ltd.
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- Shanghai Rongsheng Biotech Co., Ltd.
- Shenzhen PG Biotech Co., Ltd.
- Shanghai Upper Bio-Tech Pharma Co., Ltd.
- Beijing Leadman Biochemistry Co., Ltd.
- Blue Cross Bio-Medical (Beijing) Co., Ltd.
- Inverness Medical (Shanghai) Co., Ltd.
- Baso Diagnostics Inc.
- Beijing North Institute of Biological Technology
- Xiamen Boson Biotech Co., Ltd.
圖表
Abstract
This report
- Analyzes the operating environment of China diagnostic reagent industry
- Focuses on the development of diagnostic reagent industry
- Highlights the operation of major diagnostic reagent manufacturers in
China.
Diagnostic reagent can be divided into in vitro diagnostic (IVD) reagent and
in vivo diagnostic reagent, wherein the former always holds a larger market
share in China, accounting for 92.6% in the overall market for diagnostic
reagents in 2010. Despite a late start, China's IVD reagent industry has
achieved fast development, benefiting from the improved medical care spending,
support of national policies, etc.
The market size of China's IVD industry reached RMB12.1 billion in 2010, with
the compound annual growth rate of up to 13.8% from 2007 to 2010, higher than
the global growth of 12.6% over the corresponding period. Moreover,
considering the large population base, improved economy, etc., China's IVD
reagent industry possesses huge potential for future growth, which is expected
to hit RMB23.2 billion in 2014.
IVD products mainly consist of diagnostic reagents and instruments. In 2010,
the market size of IVD reagents climbed 13.3% YoYto RMB9.7 billion in China,
occupying 80.2% of the IVD industry. Large-scale diagnostic reagent
manufacturers are often good-sized medical test equipment producers as well,
but many Chinese enterprises only deal with diagnostic reagents. In China, the
high-end diagnostic instrument market is taken over by foreign brands, such as
Hitachi, Toshiba, Olympus, Sysmex, etc. However, after years of rapid
improvement in the field of diagnostic instrument, KehuaBio-engineering (KHB)
has become a leading domestic enterprise of diagnostic reagent and instrument.
As far as market segment is concerned, China's IVD reagents are still focused
on lower-end clinical immunology and clinical chemistry diagnostic reagents
for now, with separate market sizes up to RMB3.4 billion and RMB3.1 billion in
2010, taking 35% and 32% of China's IVD reagent market respectively. In recent
years, along with the launch of nucleic acid blood screening pilot, nucleic
acid diagnostics market has been further expanded, as of the end of 2010,
there had already been six pharmaceutical factories to declare nucleic acid
blood screening reagents to the State Food and Drug Administration (SFDA),
namely, KHB, DaAn Gene, Haoyuan Biotech, PG Biotech (later acquired by
QIAGEN), Roche and Novartis Diagnostics, which will benefit from the nucleic
acid blood screening pilot and subsequent marketing.
Table of Contents
1. Industry Profile
- 1.1 Definition and Classification
- 1.2 Industrial Chain
- 1.2.1 Upstream Market
- 1.2.2 Downstream Market
2. Operating Environment in China
- 2.1 Global Market
- 2.1.1 Development of Biopharmaceutical Industry Worldwide
- 2.1.2 Development of Diagnostic Reagent Industry Worldwide
- 2.2 Chinese Market
- 2.2.1 Development of Biopharmaceutical Industry in China
- 2.2.2 Relevant Policies of China
3. Development in China
- 3.1 Status Quo
- 3.2 Market Size
- 3.3 Competition Pattern
- 3.4 Import & Export
- 3.4.1 Import
- 3.4.2 Export
- 3.5 Market Segments
- 3.5.1 Biochemistry Diagnostic Reagent
- 3.5.2 Immune Diagnostic Reagent
- 3.5.3 Nucleic Acid Diagnostic Reagent
- 3.6 Development Tendency of Diagnostic Reagent Sector in China
4. Major Domestic Producers
- 4.1 Shanghai KehuaBio-Engineering Co., Ltd. (KHB)
- 4.1.1 Profile
- 4.1.2 Operation
- 4.1.3 Diagnostic Reagent Business
- 4.1.4 Prospects and Dynamics
- 4.2 DaAn Gene Co., Ltd. of Sun Yat-SenUniversity
- 4.2.1 Profile
- 4.2.2 Operation
- 4.2.3 Diagnostic Reagent Business
- 4.2.4 Prospects and Dynamics
- 4.3 FosunPharmaceutical (Group)Co., Ltd.
- 4.3.1 Profile
- 4.3.2 Operation
- 4.3.3 Prospects and Dynamics
- 4.3.4 Shanghai FosunLong March Medical Science Co., Ltd.
- 4.3.5 Shanghai FosunMed-Tech Development Co., Ltd.
- 4.4 BiosinoBio-Technology & Science Inc.
- 4.4.1 Profile
- 4.4.2 Operation
- 4.4.3 Prospects and Dynamics
- 4.5 Beijing KinghawkPharmaceutical Co., Ltd.
- 4.5.1 Profile
- 4.5.2 Operation
- 4.5.3 Prospects and Dynamics
- 4.6 ZhuhaiLivzonDiagnostics Inc.
- 4.6.1 Profile
- 4.6.2 Operation
- 4.7 ACON Biotech (Hangzhou) Co., Ltd.
- 4.7.1 Profile
- 4.7.2 Operation
- 4.8 Beijing WantaiBiological Pharmacy Enterprise Co., Ltd.
- 4.9 Shanghai RongshengBiotech Co., Ltd.
- 4.10 Shenzhen PG Biotech Co., Ltd.
- 4.10.1 Profile
- 4.10.2 Major Products
- 4.11 Shanghai Upper Bio-Tech PharmaCo., Ltd.
- 4.12 Beijing LeadmanBiochemistry Co., Ltd.
- 4.12.1 Profile
- 4.12.2 Operation
- 4.12.3 Prospects and Dynamics
- 4.13 Blue Cross Bio-Medical (Beijing) Co., Ltd.
- 4.14 Inverness Medical (Shanghai)Co., Ltd.
- 4.15 BasoDiagnostics Inc.
- 4.16 Beijing North Institute of Biological Technology
- 4.17 Xiamen Boson Biotech Co., Ltd.
Selected Charts
- Global Biopharmaceutical Market Scale, 2007-2012
- Global Biopharmaceutical Revenue by Region, 2009
- Market Size of IVD Industry Worldwide, 2008-2012
- China's Biopharmaceutical Sales and YoYGrowth, 2005-Jan-May 2011
- Relevant Polices of Diagnostic Reagent Industry in China
- Product Structure of Diagnostic Reagent Industry in China, 2010
- Structure of In Vitro Diagnostic Reagents in China, 2010
- Market Size and Growth Rate of In Vitro Diagnostic Industry in China,
2007-2014
- Market Size and Growth Rate of In Vitro Diagnostic Reagents in China,
2007-2014
- Major Manufacturers of IVD Products in China
- China's Import Value, Import Volume and Average Price of Contrast Agent
for X-Ray Inspection and Diagnostic Reagent for Patients, 2007-Jan.-Aug. 2011
- China's Accumulated Import Volume & Value and Proportion of Contrast Agent
for X-Ray Inspection and Diagnostic Reagent for Patients by Country of Origin,
Jan.-Aug. 2011
- Distribution of China's Imported Contrast Agent for X-Ray Inspection and
Diagnostic Reagent for Patients by Destination, 2008-Jan-Aug.2011
- China's Export Value, Export Volume and Average Price of Contrast Agent
for X-Ray Inspection and Diagnostic Reagent for Patients by Destination,
2007-Jan.-Aug. 2011
- China's Accumulated Export Volume & Value and Proportion of Contrast Agent
for X-Ray Inspection and Diagnostic Reagent for Patients by Destination,
Jan.-Aug. 2011
- Export Origins Distribution of China's Contrast Agent for X-Ray Inspection
and Diagnostic Reagent for Patients, Jan.-Aug. 2011
- China's Biochemical Reagent Market Scale, 2007-2014
- China's Immune Reagent Market Scale, 2007-2014
- Operating Revenue and Net Income of KHB, 2006-H1 2011
- Gross Margin of KHB by Product, 2008-H1 2011
- Proportion of Operating Revenue of KHB by Region, 2008-H1 2011
- Diagnostic Reagent Products of KHB
- Operating Revenue andGross Margin of KHB, 2011-2013E
- Operating Revenue and Net Income of DaAn Gene, 2006-H1 2011
- Operating Revenue of DaAn Gene by Product, 2007-H1 2011
- Gross Margin of DaAn Gene by Product, 2008-H1 2011
- Proportion of Operating Revenue of DaAn Gene by Region, 2008-H1 2011
- R&D Input and Its Ratio to Operating Revenue of DaAn Gene, 2008-2010
- Operating Revenue andGross Margin of DaAn Gene, 2011-2013E
- Operating Revenue and Net Income of FosunPharmaceutical (Group), 2006-H1
2011
- Operating Revenue andGross Margin of FosunPharmaceutical (Group),
2011-2013E
- Operation of Shanghai FosunLong March Medical Science, 2008-2009
- Operation of Shanghai FosunMed-Tech Development, 2008-2009
- Operating Revenue and Net Income of BiosinoBio-Technology & Science,
2006-H1 2011
- Operating Revenue of BiosinoBio-Technology & Science by Product, 2008-H1
2011
- Licenses and Patents for In-vitro Diagnostic Reagents of
BiosinoBio-Technology& Science, 2010
- Operating Revenue and Net Income of Beijing KinghawkPharmaceutical,
2008-H1 2011
- Operating Revenue of Beijing KinghawkPharmaceutical (by Product), 2010-H1
2011
- Operating Revenue of Beijing KinghawkPharmaceutical (by Region), 2010-H1
2011
- Operating Revenue of ZhuhaiLivzonDiagnostics, 2007-H1 2011
- Certificate Acquired by ZhuhaiLivzonDiagnostics, Jun.2010-Sep.2011
- Operation of ACON Biotech, 2008-2009
- Certificate Acquired by ACON Biotech for the Registration of Medical
Devices, Mar. 2010 & May 2011
- Operation of Beijing WantaiBiological Pharmacy, 2008-2009
- Operation of Shanghai RongshengBiotech, 2008-2009
- Operation of PG Biotech, 2008
- Detection Reagent of PG Biotech
- Operation of Shanghai Upper Bio-Tech Pharma, 2008-2009
- Diagnostic Reagents and Diagnostic Instruments of Shanghai Upper Bio-Tech
Pharma
- Operation of Beijing LeadmanBiochemistry, 2008-2009
- Operation of Blue Cross Bio-Medical (Beijing), 2008-2009
- Operation of Inverness Medical (Shanghai), 2008-2009
- Operation of BasoDiagnostics, 2008-2009
- Operation of Beijing North Institute of Biological Technology, 2008-2009
- Operation of Boson Biotech, 2009
|
 |
